No profile data available.
Jaguar Health, Inc. (JAGX) is a healthcare company in the digestive system treatment drugs industry, based in San Francisco, United States, with about 47 full-time employees.
It reported revenue of $11.51 million for fiscal year 2025, down 1.5% from fiscal year 2024, and net income of -$53.58 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.23 million, down 58.9% from a year before. Its largest business segment, Human Health, brought in 97% of segment revenue in fiscal year 2025. Its market capitalization was $9.32 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.
Jaguar Health reported $11.51 million in revenue for fiscal year 2025, down 1.5% from $11.69 million in fiscal year 2024. In Q2 2026 revenue was $1.23 million.
Human Health, with $11.16 million or 97% of segment revenue in fiscal year 2025. Next: Animal Health (3%).
$9.32 million as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Cumberland Pharmaceuticals Inc. (CPIX), Heron Therapeutics, Inc. (HRTX), Evoke Pharma, Inc. (EVOK), Curanex Pharmaceuticals Inc (CURX).